Efficient Therapy of Inflammatory Bowel Disease (IBD) with Highly Specific and Durable Targeted Ta2 C Modified with Chondroitin Sulfate (TACS)

Détails bibliographiques
Publié dans:	Advanced materials (Deerfield Beach, Fla.). - 1998. - 35(2023), 36 vom: 06. Sept., Seite e2301585
Auteur principal:	Song, Xiangping (Auteur)
Autres auteurs:	Huang, Qiong, Yang, Yuqi, Ma, Liang, Liu, Wenguang, Ou, Chunlin, Chen, Qiaohui, Zhao, Tianjiao, Xiao, Zuoxiu, Wang, Mingyuan, Jiang, Yitian, Yang, Yunrong, Zhang, Jinping, Nan, Yayun, Wu, Wei, Ai, Kelong
Format:	Article en ligne
Langue:	English
Publié:	2023
Accès à la collection:	Advanced materials (Deerfield Beach, Fla.)
Sujets:	Journal Article ROS scavenger TACS anti-inflammatory inflammatory bowel disease specific CT imaging Chondroitin Sulfates 9007-28-7 Reactive Oxygen Species

Description
Résumé:	© 2023 Wiley-VCH GmbH. Non-invasive localization of lesions and specific targeted therapy are still the main challenges for inflammatory bowel disease (IBD). Ta, as a medical metal element, has been widely used in the treatment of different diseases because of its excellent physicochemical properties but is still far from being explored in IBD. Here, Ta2 C modified with chondroitin sulfate (CS) (TACS) is evaluated as a highly targeted therapy nanomedicine for IBD. Specifically, TACS is modified with dual targeting CS functions due to IBD lesion-specific positive charges and high expression of CD44 receptors. Thanks to the acid stability, sensitive CT imaging function, and strong reactive oxygen species (ROS) elimination ability, oral TACS can accurately locate and delineate IBD lesions through non-invasive CT imaging, and specifically targeted treat IBD effectively because high levels of ROS are a central factor in the progression of IBD. As expected, TACS has much better imaging and therapeutic effects than clinical CT contrast agent and first-line drug 5-aminosalicylic acid, respectively. The mechanism of TACS treatment mainly involves protection of mitochondria, elimination of oxidative stress, inhibiting macrophage M1 polarization, protection of intestinal barrier, and restoration of intestinal flora balance. Collectively, this work provides unprecedented opportunities for oral nanomedicines to targeted therapy of IBD
Description:	Date Completed 08.09.2023 Date Revised 08.09.2023 published: Print-Electronic Citation Status MEDLINE
ISSN:	1521-4095
DOI:	10.1002/adma.202301585